Health · DR Congo
MSF Calls for Wider Access to Ervebo Vaccine as DR Congo Ebola Toll Reaches 5,700
Médecins Sans Frontières has urged a rapid expansion of access to the Ervebo vaccine in eastern DR Congo, where Ebola has caused 5,700 deaths among 11,680 confirmed cases. The vaccine is currently given only within a clinical trial, which the WHO says will add two more candidates by the end of November.
Médecins Sans Frontières (MSF) is calling for a rapid widening of access to Ervebo, the only Ebola vaccine currently available on a large scale, as the outbreak in eastern Democratic Republic of Congo continues. The latest toll stands at 11,680 confirmed cases, including 5,700 deaths, making it the deadliest Ebola epidemic in the country's history.
At present, Ervebo is being administered only within a clinical trial known as "Tumaini", the Swahili word for "hope". The vaccine is officially licensed against the Zaire strain of the virus and is being given to certain groups, such as frontline health workers. The trial aims to measure how well it works against the Bundibugyo strain, and expectations are high.
The director general of Africa CDC, the African Union's public health agency, has said on several occasions that mortality is much lower among people who have already been vaccinated.
Ervebo is not expected to remain the only vaccine in use. The World Health Organization has announced that two further vaccines will join the trial before the end of November. They are ChAdOx1, developed by the University of Oxford in partnership with an Indian pharmaceutical group, and mRNA-1469, produced by the US company Moderna.
Two other vaccine candidates are at earlier stages of development. One comes from the Egyptian group Minapharm, and the other from IAVI, a US-based international biomedical research organisation.
The appeal from MSF comes as the response to the outbreak remains under scrutiny. Another humanitarian organisation, the Norwegian Refugee Council, has also recently called for a more comprehensive and inclusive approach to the response.